Literature DB >> 33526480

Safety of the APOLLO Onyx delivery microcatheter for embolization of brain arteriovenous malformations: results from a prospective post-market study.

Philip M Meyers1, Johanna T Fifi2, Kevin M Cockroft3, Timothy R Miller4, Curtis A Given5, Ali R Zomorodi6, Bharathi D Jagadeesan7, Maxim Mokin8, Peter Kan9, Tom L Yao10, Orlando Diaz11, Daniel Huddle12, Richard J Bellon13, Joshua Seinfeld14, Adam J Polifka15, David Fiorella16, Rohan V Chitale17, Peter Kvamme18, Jay T Morrow19, Justin Singer19, Ajay K Wakhloo20, Ajit S Puri21, Vivek R Deshmukh22, Ricardo A Hanel23, L Fernando Gonzalez24, Henry H Woo25, Mohammad Ali Aziz-Sultan26.   

Abstract

BACKGROUND: Catheter retention and difficulty in retrieval have been observed during embolization of brain arteriovenous malformations (bAVMs) with the Onyx liquid embolic system (Onyx). The Apollo Onyx delivery microcatheter (Apollo) is a single lumen catheter designed for controlled delivery of Onyx into the neurovasculature, with a detachable distal tip to aid catheter retrieval. This study evaluates the safety of the Apollo for delivery of Onyx during embolization of bAVMs.
METHODS: This was a prospective, non-randomized, single-arm, multicenter, post-market study of patients with a bAVM who underwent Onyx embolization with the Apollo between May 2015 and February 2018. The primary endpoint was any catheter-related adverse event (AE) at 30 days, such as unintentional tip detachment or malfunction with clinical sequelae, or retained catheter. Procedure-related AEs (untoward medical occurrence, disease, injury, or clinical signs) and serious AEs (life threatening illness or injury, permanent physiological impairment, hospitalization, or requiring intervention) were also recorded.
RESULTS: A total of 112 patients were enrolled (mean age 44.1±17.6 years, 56.3% men), and 201 Apollo devices were used in 142 embolization procedures. The mean Spetzler-Martin grade was 2.38. The primary endpoint was not observed (0/112, 0%). The catheter tip detached during 83 (58.5%) procedures, of which 2 (2.4%) were unintentional and did not result in clinical sequelae. At 30 days, procedure related AEs occurred in 26 (23.2%) patients, and procedure-related serious AEs in 12 (10.7%). At 12 months, there were 3 (2.7%) mortalities, including 2 (1.8%) neurological deaths, none of which were device-related.
CONCLUSION: This study demonstrates the safety of Apollo for Onyx embolization of bAVMs. CLINICAL TRIAL REGISTRATION: CNCT02378883. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arteriovenous malformation; catheter; device; liquid embolic material; vascular malformation

Year:  2021        PMID: 33526480     DOI: 10.1136/neurintsurg-2020-016830

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  1 in total

1.  Initial experience with the Scepter Mini catheter for the embolization of vascular malformations in the pediatric population.

Authors:  Stavros Matsoukas; Devin Bageac; Kurt Yaeger; Alejandro Berenstein; Johanna T Fifi; Tomoyoshi Shigematsu
Journal:  Neuroradiol J       Date:  2021-10-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.